Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

BACKGROUND: Isatuximab (Isa), an anti‐CD38 monoclonal antibody, and carfilzomib (K), a next‐generation proteasome inhibitor (PI), both have potent single‐agent activity in relapsed and refractory multiple myeloma (RRMM). METHODS: This phase 1b study evaluated the combination of Isa and K in 33 patie...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer
Main Authors: Martin, Thomas G., Shah, Nina, Richter, Joshua, Vesole, David H., Wong, Sandy W., Huang, Chiung‐Yu, Madduri, Deepu, Jagannath, Sundar, Siegel, David S., Biran, Noa, Wolf, Jeffrey L., Parekh, Samir, Cho, Hearn J., Munster, Pamela, Richard, Shambavi, Ziti‐Ljajic, Samira, Chari, Ajai
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2021
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252002/
https://ncbi.nlm.nih.gov/pubmed/33735504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33448
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki